Supernus Pharmaceuticals, Inc. (SUPN)
47.81
-0.52
(-1.08%)
USD |
NASDAQ |
May 19, 14:48
Supernus Pharmaceuticals Enterprise Value : 2.462B for May 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Corcept Therapeutics, Inc. | 5.589B |
| Johnson & Johnson | 584.00B |
| Amphastar Pharmaceuticals, Inc. | 1.150B |
| Assertio Holdings, Inc. | 118.38M |
| Eli Lilly & Co. | 919.21B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.293M |
| Revenue (Quarterly) | 207.70M |
| Total Expenses (Quarterly) | 210.00M |
| EPS Diluted (Quarterly) | -0.0398 |
| Gross Profit Margin (Quarterly) | 76.15% |
| Profit Margin (Quarterly) | -1.10% |
| Earnings Yield | -1.07% |
| Normalized Earnings Yield | -0.7458 |